Atrix licenses Atrisorb GTR barrier to Block Drug; deal could generate $50 mil. in milestone payments.
This article was originally published in The Gray Sheet
Executive SummaryBLOCK DRUG TO MARKET ATRIX' ATRISORB GTR BARRIER IN U.S. and certain European markets under an agreement announced by the companies Dec. 17. The guided tissue regeneration barrier for the treatment of periodontal disease gained FDA approval in March. Atrix began selling the product in European markets during the first quarter of 1996; the firm commenced U.S. sales in July. The deal will put Atrisorb in the hands of Block's approximately 80 sales reps, who are expected to launch the product in the first quarter of 1997.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.